검색연산자 | 기능 | 검색시 예 |
---|---|---|
() | 우선순위가 가장 높은 연산자 | 예1) (나노 (기계 | machine)) |
공백 | 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 | 예1) (나노 기계) 예2) 나노 장영실 |
| | 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 | 예1) (줄기세포 | 면역) 예2) 줄기세포 | 장영실 |
! | NOT 이후에 있는 검색어가 포함된 문서는 제외 | 예1) (황금 !백금) 예2) !image |
* | 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 | 예) semi* |
"" | 따옴표 내의 구문과 완전히 일치하는 문서만 검색 | 예) "Transform and Quantization" |
BACKGROUND: Tacrolimus (FK 506) ointment is a recently developed topical immunomodulator, and preliminary studies suggest that topical application of tacrolimus is effective in the treatment of atopic dermatitis. OBJECTIVE: Our purpose was to evaluate the efficacy and safety of 0.1% tacrolimus ointment for the treatment of moderate to severe atopic dermatitis (AD) in Korea. METHOD/Patients: A total of 57 patients, 2 to 49 years of age, with moderate to severe AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. The mean age of patients was 16.7 years. One-third of the patients had severe atopic dermatitis at baseline. Efficacy was evaluated by the Eczema Area and Severity Index (EASI) score. Other evaluations were based on the physician's and patient's global evaluation of clinical response. RESULT: Significantly more patients (p<0.001) achieved clinical improvement with 0.1% tacrolimus ointment 90.0% or better. Marked improvements in the signs and symptoms of atopic dermatitis, the EASI score and the patient's assessment of pruritus were also observed early in treatment and were maintained throughout the study. Transient skin burning and itching on the application site were the most common adverse events. Occurrence of these symptoms decreased after first few days of treatment. There was no increase in incidence of other significant adverse events. CONCLUSION: 0.1% tacrolimusimus ointment is safe and effective for the treatment of Korean AD patients.
원문 PDF 다운로드
원문 URL 링크
원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)
DOI 인용 스타일